Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disordersBOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that preclinical data for ORX750, its first orexin agonist development candidate, will
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Takeda Pharmaceutical (TAK) Reports Publication of Data from Phase 2 Study of TAK-994 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development
In Patients with Narcolepsy Type 1, Oral Orexin Receptor 2 Agonist Demonstrated.